Optic Neuritis
60
8
10
30
Key Insights
Highlights
Success Rate
86% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
8.3%
5 terminated out of 60 trials
85.7%
-0.8% vs benchmark
13%
8 trials in Phase 3/4
17%
5 of 30 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 30 completed trials
Clinical Trials (60)
Treatment of Inflammatory Myelitis and Optic Neuritis With Early vs Rescue Plasma Exchange (TIMELY-PLEX)
Identification of Retinal Perivascular Inflammation in Patients With Multiple Sclerosis Using Adaptive Optics (RETIMUS)
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
The Longitudinal CONQUER Study of Rare Neuroimmunologic Disorders
Gypenosides Treatment for Optic Neuritis
Linking Optic Nerve MRI and the Retinal Axonal Loss After Optic Neuritis
Efgartigimod for the Treatment of Acute Optic Neuritis
Biobank For MS And Other Demyelinating Diseases
OCS-05 in Patients With Optic Neuritis
Building Research With Artificial Intelligence in Neuro-Ophthalmology
VIsual Pathways Model in Neuro-inflammatory Disorders
Optical Coherence Tomography and Optic Neuritis Not Related to Multiple Sclerosis
Retinal Neuro-vascular Coupling in Patients With Multiple Sclerosis
Evaluation of Optic Neuritis Using Synthetic Quantitative MRI
Edaravone in the Treatment of Optic Neuritis
Swiss Pediatric Inflammatory Brain Disease Registry (Swiss-Ped-IBrainD)
Light Stimulation to Improve Visual Function After Optic Neuritis in Persons with Multiple Sclerosis
High-Dose Vitamin D Induction in Optic Neuritis
The Effect of a Gluten Free Diet on the Permeability of the Blood Brain Barrier in Patients With CIS
Diagnosis of ON With or Without MS or NMOSD